Position in LLY
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$2,762,287
+$747,991 QoQ
Shares Held
2,303
+5.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
3.61%
of 13F equity value
Holder Rank
#2,200
of 4,605 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Saxony Capital Management, LLC holds $4,819,156 across 7 Drug Manufacturers - General names. LLY ranks #1 (57.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
This page
|
2,303 | $2,762,287 | |
| 2 | ABBV |
AbbVie Inc.
|
2,538 | $638,662 | |
| 3 | JNJ |
Johnson & Johnson
|
1,989 | $505,146 | |
| 4 | AZN |
Astrazeneca PLC
|
1,275 | $241,765 | |
| 5 | AMGN |
Amgen Inc
|
625 | $226,325 | |
| 6 | GSK |
GSK plc
|
4,307 | $225,772 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
1,735 | $219,199 |
All Filings in LLY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,762,287 | 2,303 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $2,014,296 | 2,190 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $2,351,400 | 2,188 | Shares | Sole | 2026-01-15 | |
| 2025-09-30 | $1,688,519 | 2,213 | Shares | Sole | 2025-10-21 | |
| 2025-06-30 | $1,693,918 | 2,173 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $1,770,751 | 2,144 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $1,695,312 | 2,196 | Shares | Sole | 2025-01-23 | |
| 2024-09-30 | $2,025,258 | 2,286 | Shares | Sole | 2024-10-22 | |
| 2024-06-30 | $1,920,310 | 2,121 | Shares | Sole | 2024-07-26 | |
| 2024-03-31 | $1,418,999 | 1,824 | Shares | Sole | 2024-04-30 | |
| 2023-12-31 | $887,787 | 1,523 | Shares | Sole | 2024-01-29 | |
| No filing history on record for this holder in this stock. | ||||||